Search Results

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.

DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will give a presentation at Stora Aktiedagarna in Stockholm on June 11-12.

Elicio Therapeutics, Inc. today announced the pricing of an approximately $11.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and accompanying common warrants to purchase common stock, before deducting underwriting discounts and commissions and estimated offering expenses payable by Elicio.

The New England Journal of Medicine has published results from a positive phase 3 study of Dupixent in children aged one to 11 years with eosinophilic esophagitis.

Inozyme Pharma, Inc. announced a data presentation and sponsored symposium at the 11th International Conference on Children’s Bone Health, which is being held June 22-25, 2024, in Salzburg, Austria.

Avinger, Inc. announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. into a shares of a new series of convertible preferred stock.

ChromaDex Corp. announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, June 11, 2024, at 2:00pm PST.

Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.

Merck and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.